Evidence map›Paper›PMID 36309358›Full record

ArticleIn vivo (Athens, Greece)

Interstitial Brachytherapy of the Liver for Renal Cell Carcinoma: ADC Measurements Do Not Predict Overall Survival.

Maximilian Thormann, Franziska Heitmann, Vanessa Wrobel, Christine March, Maciej Pech, Alexey Surov, Robert Damm, Jazan Omari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Maximilian ThormannUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany maximilian.thormann@med.ovgu.de.
Franziska HeitmannUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Vanessa WrobelUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Christine MarchUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Maciej PechUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Alexey SurovUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Robert DammUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.
Jazan OmariUniversity Clinic for Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo assess the influence of pre-treatment apparent diffusion coefficient (ADC) measurements on outcomes in patients undergoing interstitial brachytherapy (iBT) for liver metastases from renal cell carcinoma. PATIENTS AND

methodsPatients undergoing iBT for renal cell carcinoma (RCC) liver metastases were retrospectively identified. Patients were eligible for inclusion if they had a pre-treatment magnetic resonance imaging (MRI) with diffusion weighted imaging (DWI) sequences. For each lesion, a region of interest (ROI) was placed along the contours of the entire lesion across all slices. For each ROI, ADC minimum, mean and maximum as well as the lesion area were noted, and the average was calculated for each lesion. ADC measurements were correlated with overall survival.

resultsThe analysis included 17 patients. Median overall survival was 36 months. Neither ADC measurement was significantly associated with overall survival. ADC min (HR=1.00, 95%CI=1.00-1.00, p=0.600), ADC max (HR=1.001, 95%CI=0.998-1.003, p=0.490), ADC mean (HR=0.999, 95%CI=0.996-1.003, p=0.638).

conclusionADC is not able to differentiate between groups with good and bad overall survival in patients undergoing iBT for RCC liver metastases.

Indexed as

BrachytherapyCarcinoma, Renal CellKidney NeoplasmsLiver NeoplasmsDiffusion Magnetic Resonance ImagingHumansRetrospective Studiesapparent diffusion coefficientinterstitial brachytherapyliver metastasesoverall survivalRenal cell carcinoma

Identifiers

PMID36309358
PMCPMC9677782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.